Back to top
more

Ecolab (ECL)

(Delayed Data from NYSE)

$244.57 USD

244.57
1,399,786

-1.16 (-0.47%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $244.55 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (142 out of 250)

Industry: Chemical - Specialty

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

These 2 Basic Materials Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Here's Why You Should Hold Lantheus (LNTH) in Your Portfolio Now

by Zacks Equity Research

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

GE HealthCare (GEHC) Q1 Earnings In Line, Sales Volume Decline

by Zacks Equity Research

GE HealthCare's (GEHC) first-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.

Ecolab (ECL) Q1 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Ecolab's (ECL) robust performance across the majority of its segments drives its first-quarter sales despite business challenges.

Ecolab (ECL) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Ecolab (ECL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ecolab (ECL) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Ecolab (ECL) delivered earnings and revenue surprises of 0.75% and 0.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Revvity (RVTY) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Revvity's (RVTY) first-quarter results showcase a decline in life sciences segmental revenues. However, the company's earnings and revenues beat their respective estimates.

U.S. Silica (SLCA) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

U. S. Silica's (SLCA) earnings and sales miss estimates in the first quarter amid lower sales volumes in Oil & Gas.

Bruker's (BRKR) Balanced Segmental Growth, Innovation Aid

by Zacks Equity Research

Bruker (BRKR) revenues continue to be driven by the strength of end markets, including academic, government and industrial.

Is Ecolab (ECL) Stock Outpacing Its Basic Materials Peers This Year?

by Zacks Equity Research

Here is how Ecolab (ECL) and Pan American Silver (PAAS) have performed compared to their sector so far this year.

Indrajit Bandyopadhyay headshot

What's in Store for These 5 Medical Device Stocks in Q1 Earnings?

by Indrajit Bandyopadhyay

Here is a sneak peek into how the five medical device stocks, SYK, GEHC, ECL, NARI and MMSI, might fare in their quarterly results slated to be released tomorrow.

Philips (PHG) Receives FDA Warning Letter Regarding CT Systems

by Zacks Equity Research

Philips (PHG) receives a warning letter from the FDA in respect of a manufacturing plant in China regarding faults in the manufacturing of CT systems.

Factors Setting the Tone for Ecolab's (ECL) Q1 Earnings

by Zacks Equity Research

Ecolab's (ECL) first-quarter results are likely to reflect continued segmental strength.

Reliance's (RS) Earnings & Revenues Miss Estimates in Q1

by Zacks Equity Research

Reliance's (RS) first-quarter earnings and sales lag their respective estimates on lower shipments and prices.

Agnico Eagle's (AEM) Q1 Earnings and Sales Beat Estimates

by Zacks Equity Research

Agnico Eagle's (AEM) first-quarter earnings and revenues exceed expectations, driven by increased production and higher realized gold prices.

DexCom (DXCM) Q1 Earnings Beat, Strong CGM Demand Continues

by Zacks Equity Research

DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

Newmont's (NEM) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Newmont's (NEM) first-quarter earnings and revenues exceed expectations, driven by increased production and higher realized gold prices.

Revvity's (RVTY) New Launch to Boost Tuberculosis Testing

by Zacks Equity Research

Revvity's (RVTY) latest offering is likely to provide a new and improved workflow to lower hands-on time and enable increased lab productivity.

CONMED (CNMD) Q1 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

CONMED's (CNMD) adjusted first-quarter earnings and revenues beat estimates on the back of strong U.S. and International markets as well as supply-chain improvement.

Veeva's (VEEV) AI Partner Program to Develop GenAI Solutions

by Zacks Equity Research

Veeva (VEEV) announces the Veeva AI Partner Program, which is expected to provide partners assistance to combine Generative AI solutions with Veeva Vault applications.

West Pharmaceutical (WST) Q1 Earnings Beat, HVP Sales Weak

by Zacks Equity Research

West Pharmaceutical's (WST) first-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.

Unveiling Ecolab (ECL) Q1 Outlook: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Ecolab (ECL), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Methanex's (MEOH) Q1 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Adjusted EBITDA of Methanex (MEOH) is hurt by lower year-over-year average realized prices in Q1.

Cleveland-Cliffs (CLF) Earnings & Revenues Lag Estimates in Q1

by Zacks Equity Research

Cleveland-Cliffs (CLF) lags Q1 earnings and revenue estimates due to lower volumes.

Penumbra's (PEN) New Launch to Enhance Blood Clot Removal

by Zacks Equity Research

Penumbra's (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.